ATA Action urges FDA to adopt risk-based framework for AI medical devices; policy proposal in the works
ATA Action asked the FDA for a risk-based framework for AI-enabled medical devices. The FDA's weekly roundup mentions an AI policy proposal, and analyses discuss the effects of oversight of generative AI devices.
Who is affected and how
- medtech company
- The classification of generative AI devices and the change-management plan should be clarified at an early stage of development.
- hospital manager
- Institutions need to track their device inventory and manufacturers' risk classifications.
Sources
- ATA Action urges FDA to build risk-based framework for AI-enabled medical deviceshme news · Oct 26, 2026
- Why FDA's AI Framework Falls Short for Agentic Medical Devicesmddionline.com · Oct 26, 2026
- AdvaMed Encourages Risk-Based FDA Approach to Generative AI Medical Devices - AdvaMed®advamed.org · Oct 27, 2026
- AdvaMed Urges FDA to Use Existing Regulatory Framework for GenAIfdaweb.com · Oct 27, 2026
- How FDA generative AI device oversight may impact providersmodern healthcare · Oct 30, 2026
- How FDA generative AI device oversight may impact providers - Modern Healthcaremodernhealthcare.com · Oct 30, 2026
- This Week at FDA: New ConOps for drug inspections, AI policy proposal, and moreraps · Oct 30, 2026
- This Week at FDA: New ConOps for drug inspections, AI policy proposal, and more - RAPS — The 8088the8088.com · Oct 30, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.